Tempest Therapeutics
$2.15
117
+$0.04+1.9% Tuesday 20:00
Statistics
Day High
2.16
Day Low
2.06
52W High
5.92
52W Low
1.28
Volume
121,976
Avg. Volume
-
Mkt Cap
9.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-0.28
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-83.69MNet Income
Analyst Ratings
11Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TPST. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Merck
MRK
Mkt Cap277.02B
Pfizer
PFE
Mkt Cap149.77B
Gilead Sciences
GILD
Mkt Cap163.4B
AMGEN
AMGN
Mkt Cap178B
Novartis
NVS
Mkt Cap279.67B
Roche
RHHBY
Mkt Cap328.49B
Astrazeneca
AZN
Mkt Cap286.4B
Johnson & Johnson
JNJ
Mkt Cap546.9B
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
About
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Show more...
CEO
Mr. Nicholas Maestas
Employees
24
Country
United States
ISIN
US87978U2078
Listings
0 Comments
Share your thoughts
FAQ
What is Tempest Therapeutics stock price today?▼
The current price of TPST is $2.15 USD — it has increased by +1.9% in the past 24 hours. Watch Tempest Therapeutics stock price performance more closely on the chart.
What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tempest Therapeutics stocks are traded under the ticker TPST.
Is Tempest Therapeutics stock price growing?▼
TPST stock has risen by +23.56% compared to the previous week, the month change is a +35.22% rise, over the last year Tempest Therapeutics has showed a -35.53% decrease.
What is Tempest Therapeutics market cap?▼
Today Tempest Therapeutics has the market capitalization of 9.55M
When is the next Tempest Therapeutics earnings date?▼
Tempest Therapeutics is going to release the next earnings report on May 07, 2026.
What were Tempest Therapeutics earnings last quarter?▼
TPST earnings for the last quarter are -0.79 USD per share, whereas the estimation was -3.27 USD resulting in a +75.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tempest Therapeutics revenue for the last year?▼
Tempest Therapeutics revenue for the last year amounts to 0 USD.
What is Tempest Therapeutics net income for the last year?▼
TPST net income for the last year is -83.69M USD.
How many employees does Tempest Therapeutics have?▼
As of May 06, 2026, the company has 24 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health & Wellness sector.
When did Tempest Therapeutics complete a stock split?▼
The last stock split for Tempest Therapeutics was on January 30, 2026 with a ratio of 2:1.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in Brisbane, United States.